Deciphering Vaccines for COVID-19: where do we stand today?

Immunopharmacol Immunotoxicol. 2021 Feb;43(1):8-21. doi: 10.1080/08923973.2020.1837867. Epub 2020 Oct 25.

Abstract

Pneumonia of unknown etiology was detected in a few patients in Wuhan City, Hubei Province, China. The causative agent was named as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the World Health Organization (WHO). The disease caused by this virus was named as a new coronavirus disease: COVID-19. The disease has a global impact affecting more than 200 nations including the USA, India, Brazil, Russia, and Peru are the 5 most severely affected nations. The discovery of the genotype and phenotype of SARS-CoV-2 boosted the global efforts for the development of treatment options and vaccines for the COVID-19. As the transmission of the virus is rapid, to protect the global population, the development of an effective vaccine against the virus is very essential. The current review highlights the various platforms and technologies used globally for the development of the vaccine and also focuses on the current status of the vaccine candidates under development by organizations to combat the global threat of COVID-19 pandemic.

Keywords: COVID-19; nucleic acid-based vaccine; protein-based vaccine; vaccine; viral vector-based vaccine.

Publication types

  • Review

MeSH terms

  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / therapeutic use*
  • Genetic Vectors / immunology
  • Humans
  • Pandemics / prevention & control
  • RNA, Viral / immunology
  • Viral Proteins / immunology

Substances

  • COVID-19 Vaccines
  • RNA, Viral
  • Viral Proteins